Alembic Q2 Review: Net Profit Rose To ₹153 Crore, U.S Generics Witness 5% Growth
Alembic Pharmaceuticals Ltd.'s Q2FY25 sales came in line with our estimates while operating performance was below. After adjusting for the extraordinary income from insurance claim, Adjusted profit after tax also came below estimates.
NDTV Profit talked with Shaunak Amin, Managing director of Alembic Pharmaceuticals Ltd
Watch video Alembic Q2 Review: Net Profit Rose To ₹153 Crore, U.S Generics Witness 5% Growth online without registration, duration hours minute second in high quality. This video was added by user NDTV Profit Markets 08 November 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 12 once and liked it people.